Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3909 Tablets Versus Investigator's Choice in Relapsed/Refractory CLL/SLL
NCT07753369Phase 3Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 3 trial of TQB3909 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
TQB3909
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07753369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753369.